A review of emerging trends in the treatment of tuberculosis

Artificial Cells, Nanomedicine and Biotechnology

Volumn 44, Issue 2, 2016, Pages 478-484

  Kaur, Manpreet ^a   Garg, Tarun ^a   Narang, R K ^a  

^a ISF COLLEGE OF PHARMACY   (India)

Author keywords

Anti tubercular drugs; Drug targeting; Liposomes; Novel drug delivery systems

Indexed keywords

BIOMATERIALS; LIPOSOMES; MICROORGANISMS;

ANTI TUBERCULARS; DRUG DELIVERY SYSTEM; DRUG-TARGETING; MYCOBACTERIUM TUBERCULOSIS; NANOSTRUCTURED BIOMATERIALS; PHYSICOCHEMICAL PROPERTY; SOLID LIPID NANOPARTICLE (SLN); THERAPEUTIC EFFICIENCY;

DRUG INTERACTIONS;

ETHAMBUTOL; ISONIAZID; MICROSPHERE; PYRAZINAMIDE; RIFAMPICIN; SOLID LIPID NANOPARTICLE; STREPTOMYCIN; LIPOSOME; NANOPARTICLE; TUBERCULOSTATIC AGENT;

ENCAPSULATION; HUMAN; LIPOSOMAL DELIVERY; REVIEW; SURFACE AREA; SUSTAINED DRUG RELEASE; TREATMENT OUTCOME; TUBERCULOSIS; CHEMISTRY; TRANSMISSION;

ANTITUBERCULAR AGENTS; HUMANS; LIPOSOMES; MICROSPHERES; NANOPARTICLES; TUBERCULOSIS;

EID: 84964355319     PISSN: 21691401     EISSN: 2169141X     Source Type: Journal    
DOI: 10.3109/21691401.2014.962745     Document Type: Review

References (42)

1. Ahmad Z, Sharma S, Khuller GK 2005. Inhalable alginate nanoparticles as antitubercular drug carriers against experimental tuberculosis. Int J Antimicrob Agents. 26:298-303.
2. Barrow EL, Winchester GA, Staas JK, Quenelle DC, Barrow WW 1998. Use of microsphere technology for targeted delivery of rifampin to Mycobacterium tuberculosis-infected macrophages. Antimicrob Agents Chemother. 42:2682-2689.
3. El-Ridy MS, Mostafa DM, Shehab A, Nasr EA, Abd El-Alim S. 2007. Biological evaluation of pyrazinamide liposomes for treatment of Mycobacterium tuberculosis. Int J Pharm. 330:82-88.
4. Gabor F, Bogner E, Weissenboeck A, Wirth M. 2004. The lectin-cell interaction and its implications to intestinal lectin-mediated drug delivery. Adv Drug Deliv Rev. 56:459-480.
5. Gagandeep, Garg T, Malik B, Rath G, Goyal AK. 2014. Development and characterization of nano-fiber patch for the treatment of glaucoma. Eur J Pharm Sci. 53:10-16.
6. Gangadharam PR, Ashtekar DA, Ghori N, Goldstein JA, Debs RJ, Duzgunes N. 1991. Chemotherapeutic potential of free and liposome encapsulated streptomycin against experimental Mycobacterium avium complex infections in beige mice. J Antimicrob Chemother. 28:425-435.
7. Garcia-Contreras L, Fiegel J, Telko MJ, Elbert K, Hawi A, Thomas M, et al 2007. Inhaled large porous particles of capreomycin for treatment of tuberculosis in a guinea pig model. Antimicrob Agents Chemother. 51:2830-2836.
8. Garg T. 2014. Current nanotechnological approaches for an effective delivery of bio-active drug molecules in the treatment of acne. Artif Cells Nanomed Biotechnol. 1-8.
9. Garg T, Goyal AK 2012. Iontophoresis: Drug delivery system by applying an electrical potential across the skin. Drug Deliv Lett. 2:270-280.
10. Garg T, Goyal AK 2014a. Biomaterial-based scaffolds-current status and future directions. Expert Opin Drug Deliv. 11:767-789.
11. Garg T, Goyal AK 2014b. Liposomes: Targeted and controlled delivery system. Drug Deliv Lett. 4:62-71.
12. Garg T, Goyal AK, Arora S, Murthy R. 2012a. Development, optimization & evaluation of porous chitosan scaffold formulation of gliclazide for the treatment of type-2 diabetes mellitus. Drug Deliv Lett. 2:251-261.
13. Garg T, Singh O, Arora S, Murthy R. 2012b. Scaffold: a novel carrier for cell and drug delivery. Crit Rev Ther Drug Carrier Syst. 29:1-63.
14. Garg T, Singh S, Goyal AK 2013. Stimuli-sensitive hydrogels: an excellent carrier for drug and cell delivery. Crit Rev Ther Drug Carrier Syst. 30:369-409.
15. Gelperina S, Kisich K, Iseman MD, Heifets L. 2005. The potential advantages of nanoparticle drug delivery systems in chemotherapy of tuberculosis. Am J Respir Crit Care Med. 172:1487-1490.
16. Goyal AK, Rath G, Garg T. 2013a. Nanotechnological approaches for genetic immunization. DNA and RNA Nanobiotechnologies in Medicine: Diagnosis and Treatment of Diseases 67-120.
17. Goyal G, Garg T, Malik B, Chauhan G, Rath G, Goyal AK 2013b. Development and characterization of niosomal gel for topical delivery of benzoyl peroxide. Drug Deliv.
18. Goyal G, Garg T, Rath G, Goyal AK 2014. Current nanotechnological strategies for an effective delivery of drugs in treatment of periodontal disease. Crit Rev Ther Drug Carrier Syst. 31:89-119.
19. Johal HS, Garg T, Rath G, Goyal AK 2014. Advanced topical drug delivery system for the management of vaginal candidiasis. Drug Deliv. 1-14.
20. Joshi D, Garg T, Goyal AK, Rath G. 2014. Advanced drug delivery approaches against periodontitis. Drug Deliv. 1-15.
21. Kataria K, Sharma A, Garg T, Goyal AK, Rath G. 2014. Novel technology to improve drug loading in polymeric nanofibers. Drug Deliv Lett. 4:79-86.
22. Kaur M, Garg T, Rath G, Goyal AK 2014a. Current nanotechnological strategies for effective delivery of bioactive drug molecules in the treatment of tuberculosis. Crit Rev Ther Drug Carrier Syst. 31: 49-88.
23. Kaur M, Malik B, Garg T, Rath G, Goyal AK 2014b. Development and characterization of guar gum nanoparticles for oral immunization against tuberculosis. Drug Deliv.
24. Kaur R, Garg T, Das Gupta U, Gupta P, Rath G, Goyal AK 2014c. Preparation and characterization of spray-dried inhalable powders containing nanoaggregates for pulmonary delivery of anti-tubercular drugs. Artif Cells Nanomed Biotechnol. 1-6.
25. Kaur R, Garg T, Malik B, Gupta UD, Gupta P, Rath G, Goyal AK 2014d. Development and characterization of spray-dried porous nano-aggregates for pulmonary delivery of anti-tubercular drugs. Drug Deliv. 1-6.
26. Klemens SP, Cynamon MH, Swenson CE, Ginsberg RS 1990. Liposome-encapsulated-gentamicin therapy of Mycobacterium avium complex infection in beige mice. Antimicrob Agents Chemother. 34:967-970.
27. Kumar PV, Agashe H, Dutta T, Jain NK 2007. PEGylated dendritic architecture for development of a prolonged drug delivery system for an antitubercular drug. Curr Drug Deliv. 4:11-19.
28. Lu D, Garcia-Contreras L, Xu D, Kurtz SL, Liu J, Braunstein M, et al 2007. Poly (lactide-co-glycolide) microspheres in respirable sizes enhance an in vitro T cell response to recombinant Mycobacterium tuberculosis antigen 85B. Pharm Res. 24:1834-1843.
29. Marwah H, Garg T, Goyal AK, Rath G. 2014. Permeation enhancer strategies in transdermal drug delivery. Drug Deliv. 1-15.
30. Pandey R, Khuller GK 2005a. Antitubercular inhaled therapy: opportunities, progress and challenges. J Antimicrob Chemother. 55:430-435.
31. Pandey R, Khuller GK 2005b. Solid lipid particle-based inhalable sustained drug delivery system against experimental tuberculosis. Tuberculosis (Edinb). 85:227-234.
32. Pandey R, Sharma A, Zahoor A, Sharma S, Khuller GK, Prasad B. 2003. Poly (DL-lactide-co-glycolide) nanoparticle-based inhalable sustained drug delivery system for experimental tuberculosis. J Antimicrob Chemother. 52:981-986.
33. Pandey R, Sharma S, Khuller GK 2005. Oral solid lipid nanoparticle-based antitubercular chemotherapy. Tuberculosis (Edinb). 85: 415-420.
34. Parnami N, Garg T, Rath G, Goyal AK 2013. Development and characterization of nanocarriers for topical treatment of psoriasis by using combination therapy. Artif Cells Nanomed Biotechnol.
35. Qurrat ul A, Sharma S, Khuller GK, Garg SK 2003. Alginate-based oral drug delivery system for tuberculosis: pharmacokinetics and therapeutic effects. J Antimicrob Chemother. 51:931-938.
36. Sharma A, Garg T, Aman A, Panchal K, Sharma R, Kumar S, Markandeywar T. 2014a. Nanogel-an advanced drug delivery tool: Current and future. Artif Cells Nanomed Biotechnol. 1-13.
37. Sharma A, Sharma S, Khuller GK 2004. Lectin-functionalized poly (lactide-co-glycolide) nanoparticles as oral/aerosolized antitubercular drug carriers for treatment of tuberculosis. J Antimicrob Chemother. 54:761-766.
38. Sharma R, Singh H, Joshi M, Sharma A, Garg T, Goyal AK, Rath G. 2014b. Recent advances in polymeric electrospun nanofibers for drug delivery. Crit Rev Ther Drug Carrier Syst. 31:187-217.
39. Singh B, Garg T, Goyal AK, Rath G. 2014a. Recent advancements in the cardiovascular drug carriers. Artif Cells Nanomed Biotechnol. 1-10.
40. Singh H, Sharma R, Joshi M, Garg T, Goyal AK, Rath G. 2014b. Transmucosal delivery of Docetaxel by mucoadhesive polymeric nanofibers. Artif Cells Nanomed Biotechnol.
41. Suarez S, O'Hara P, Kazantseva M, Newcomer CE, Hopfer R, Mcmurray DN, Hickey AJ 2001. Respirable PLGA microspheres containing rifampicin for the treatment of tuberculosis: screening in an infectious disease model. Pharm Res. 18:1315-1319.
42. Vyas SP, Kannan ME, Jain S, Mishra V, Singh P. 2004. Design of liposomal aerosols for improved delivery of rifampicin to alveolar macrophages. Int J Pharm. 269:37-49.